CYP3A activity in European American and Japanese men using midazolam as an in vivo probe

Tomonori Tateishi, Minoru Watanabe, Hironori Nakura, Masako Asoh, Hiroaki Shirai, Yoshihiro Mizorogi, Shinichi Kobayashi, Kenneth E. Thummel, Grant R. Wilkinson

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Objective: To investigate putative differences in CYP3A activity between European American and Japanese subjects using midazolam as an in vivo probe. Methods: Midazolam was administered orally (2 mg) to 22 young healthy Japanese men and, on a separate occasion, to 19 of these by the intravenous route (1 mg). The disposition of the drug and its 1′-hydroxy metabolite were determined and compared with data collected in a similar fashion in 20 young healthy European American men. Results: Plasma concentrations of midazolam, especially those attained soon after drug administration, were higher after intravenous injection in Japanese subjects than those in European American men. This observation was associated with smaller initial (2.5-fold) and steady-state (1.8-fold) volumes of distribution for the drug; normalization for body weight only modestly reduced these differences. The systemic clearance value of midazolam was 25% lower (P <.03) in Japanese subjects, but this difference was not apparent after accounting for the smaller body weights of that group. No statistical differences were noted in the elimination half-life (t1/2) of midazolam between European American and Japanese subjects. Much greater interindividual variability was observed after oral administration compared with intravenous administration, but significant differences were not found between the 2 groups with respect to the maximum midazolam plasma level or its oral clearance. Absolute oral bioavailability and its associated gastrointestinal and hepatic extraction ratios also showed no statistically significant interracial differences. Conclusions: On average, hepatic CYP3A, as measured by the metabolism of midazolam, is lower in young healthy Japanese men compared with similar European Americans. However, there is considerable interindividual variability, and body size appears to be an important determinant. After oral administration, even greater variability in the plasma level-time profile of midazolam is present, and no statistically significant or clinically important interracial/ethnic difference is present. Possibly because of smaller body mass and differences in body composition, midazolam has a smaller distribution volume(s) in Japanese men than in European American men that might be an important factor when drugs are administered intravenously.

Original languageEnglish
Pages (from-to)333-339
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume69
Issue number5
DOIs
Publication statusPublished - May 2001
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP3A
Midazolam
Pharmaceutical Preparations
Oral Administration
Body Weight
Liver
Body Size
Body Composition
Intravenous Injections
Intravenous Administration
Biological Availability
Half-Life

ASJC Scopus subject areas

  • Pharmacology

Cite this

CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. / Tateishi, Tomonori; Watanabe, Minoru; Nakura, Hironori; Asoh, Masako; Shirai, Hiroaki; Mizorogi, Yoshihiro; Kobayashi, Shinichi; Thummel, Kenneth E.; Wilkinson, Grant R.

In: Clinical Pharmacology and Therapeutics, Vol. 69, No. 5, 05.2001, p. 333-339.

Research output: Contribution to journalArticle

Tateishi, T, Watanabe, M, Nakura, H, Asoh, M, Shirai, H, Mizorogi, Y, Kobayashi, S, Thummel, KE & Wilkinson, GR 2001, 'CYP3A activity in European American and Japanese men using midazolam as an in vivo probe', Clinical Pharmacology and Therapeutics, vol. 69, no. 5, pp. 333-339. https://doi.org/10.1067/mcp.2001.115447
Tateishi, Tomonori ; Watanabe, Minoru ; Nakura, Hironori ; Asoh, Masako ; Shirai, Hiroaki ; Mizorogi, Yoshihiro ; Kobayashi, Shinichi ; Thummel, Kenneth E. ; Wilkinson, Grant R. / CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. In: Clinical Pharmacology and Therapeutics. 2001 ; Vol. 69, No. 5. pp. 333-339.
@article{94d6fd49d8794a2db308baf8cda86825,
title = "CYP3A activity in European American and Japanese men using midazolam as an in vivo probe",
abstract = "Objective: To investigate putative differences in CYP3A activity between European American and Japanese subjects using midazolam as an in vivo probe. Methods: Midazolam was administered orally (2 mg) to 22 young healthy Japanese men and, on a separate occasion, to 19 of these by the intravenous route (1 mg). The disposition of the drug and its 1′-hydroxy metabolite were determined and compared with data collected in a similar fashion in 20 young healthy European American men. Results: Plasma concentrations of midazolam, especially those attained soon after drug administration, were higher after intravenous injection in Japanese subjects than those in European American men. This observation was associated with smaller initial (2.5-fold) and steady-state (1.8-fold) volumes of distribution for the drug; normalization for body weight only modestly reduced these differences. The systemic clearance value of midazolam was 25{\%} lower (P <.03) in Japanese subjects, but this difference was not apparent after accounting for the smaller body weights of that group. No statistical differences were noted in the elimination half-life (t1/2) of midazolam between European American and Japanese subjects. Much greater interindividual variability was observed after oral administration compared with intravenous administration, but significant differences were not found between the 2 groups with respect to the maximum midazolam plasma level or its oral clearance. Absolute oral bioavailability and its associated gastrointestinal and hepatic extraction ratios also showed no statistically significant interracial differences. Conclusions: On average, hepatic CYP3A, as measured by the metabolism of midazolam, is lower in young healthy Japanese men compared with similar European Americans. However, there is considerable interindividual variability, and body size appears to be an important determinant. After oral administration, even greater variability in the plasma level-time profile of midazolam is present, and no statistically significant or clinically important interracial/ethnic difference is present. Possibly because of smaller body mass and differences in body composition, midazolam has a smaller distribution volume(s) in Japanese men than in European American men that might be an important factor when drugs are administered intravenously.",
author = "Tomonori Tateishi and Minoru Watanabe and Hironori Nakura and Masako Asoh and Hiroaki Shirai and Yoshihiro Mizorogi and Shinichi Kobayashi and Thummel, {Kenneth E.} and Wilkinson, {Grant R.}",
year = "2001",
month = "5",
doi = "10.1067/mcp.2001.115447",
language = "English",
volume = "69",
pages = "333--339",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - CYP3A activity in European American and Japanese men using midazolam as an in vivo probe

AU - Tateishi, Tomonori

AU - Watanabe, Minoru

AU - Nakura, Hironori

AU - Asoh, Masako

AU - Shirai, Hiroaki

AU - Mizorogi, Yoshihiro

AU - Kobayashi, Shinichi

AU - Thummel, Kenneth E.

AU - Wilkinson, Grant R.

PY - 2001/5

Y1 - 2001/5

N2 - Objective: To investigate putative differences in CYP3A activity between European American and Japanese subjects using midazolam as an in vivo probe. Methods: Midazolam was administered orally (2 mg) to 22 young healthy Japanese men and, on a separate occasion, to 19 of these by the intravenous route (1 mg). The disposition of the drug and its 1′-hydroxy metabolite were determined and compared with data collected in a similar fashion in 20 young healthy European American men. Results: Plasma concentrations of midazolam, especially those attained soon after drug administration, were higher after intravenous injection in Japanese subjects than those in European American men. This observation was associated with smaller initial (2.5-fold) and steady-state (1.8-fold) volumes of distribution for the drug; normalization for body weight only modestly reduced these differences. The systemic clearance value of midazolam was 25% lower (P <.03) in Japanese subjects, but this difference was not apparent after accounting for the smaller body weights of that group. No statistical differences were noted in the elimination half-life (t1/2) of midazolam between European American and Japanese subjects. Much greater interindividual variability was observed after oral administration compared with intravenous administration, but significant differences were not found between the 2 groups with respect to the maximum midazolam plasma level or its oral clearance. Absolute oral bioavailability and its associated gastrointestinal and hepatic extraction ratios also showed no statistically significant interracial differences. Conclusions: On average, hepatic CYP3A, as measured by the metabolism of midazolam, is lower in young healthy Japanese men compared with similar European Americans. However, there is considerable interindividual variability, and body size appears to be an important determinant. After oral administration, even greater variability in the plasma level-time profile of midazolam is present, and no statistically significant or clinically important interracial/ethnic difference is present. Possibly because of smaller body mass and differences in body composition, midazolam has a smaller distribution volume(s) in Japanese men than in European American men that might be an important factor when drugs are administered intravenously.

AB - Objective: To investigate putative differences in CYP3A activity between European American and Japanese subjects using midazolam as an in vivo probe. Methods: Midazolam was administered orally (2 mg) to 22 young healthy Japanese men and, on a separate occasion, to 19 of these by the intravenous route (1 mg). The disposition of the drug and its 1′-hydroxy metabolite were determined and compared with data collected in a similar fashion in 20 young healthy European American men. Results: Plasma concentrations of midazolam, especially those attained soon after drug administration, were higher after intravenous injection in Japanese subjects than those in European American men. This observation was associated with smaller initial (2.5-fold) and steady-state (1.8-fold) volumes of distribution for the drug; normalization for body weight only modestly reduced these differences. The systemic clearance value of midazolam was 25% lower (P <.03) in Japanese subjects, but this difference was not apparent after accounting for the smaller body weights of that group. No statistical differences were noted in the elimination half-life (t1/2) of midazolam between European American and Japanese subjects. Much greater interindividual variability was observed after oral administration compared with intravenous administration, but significant differences were not found between the 2 groups with respect to the maximum midazolam plasma level or its oral clearance. Absolute oral bioavailability and its associated gastrointestinal and hepatic extraction ratios also showed no statistically significant interracial differences. Conclusions: On average, hepatic CYP3A, as measured by the metabolism of midazolam, is lower in young healthy Japanese men compared with similar European Americans. However, there is considerable interindividual variability, and body size appears to be an important determinant. After oral administration, even greater variability in the plasma level-time profile of midazolam is present, and no statistically significant or clinically important interracial/ethnic difference is present. Possibly because of smaller body mass and differences in body composition, midazolam has a smaller distribution volume(s) in Japanese men than in European American men that might be an important factor when drugs are administered intravenously.

UR - http://www.scopus.com/inward/record.url?scp=0035338739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035338739&partnerID=8YFLogxK

U2 - 10.1067/mcp.2001.115447

DO - 10.1067/mcp.2001.115447

M3 - Article

VL - 69

SP - 333

EP - 339

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -